BRAF and neoplasm: Although the use of BRAF inhibitor to target MAPK-dysregulated tumours was found to be a promising therapy [73,74], the response duration was limited owing mainly to the reactivation of MAPK by multiple mechanisms, as observed in melanoma, a typical BRAF-mutated tumour.